mecamylamine has been researched along with Chronic Disease in 5 studies
Mecamylamine: A nicotinic antagonist that is well absorbed from the gastrointestinal tract and crosses the blood-brain barrier. Mecamylamine has been used as a ganglionic blocker in treating hypertension, but, like most ganglionic blockers, is more often used now as a research tool.
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
Excerpt | Relevance | Reference |
---|---|---|
" The safety and bioactivity of topical mecamylamine, an antagonist of nACh receptors, was tested in patients with diabetic macular edema." | 9.14 | Topical mecamylamine for diabetic macular edema. ( Campochiaro, PA; Channa, R; Cooke, JP; Do, DV; Hafiz, G; Heier, JS; Hsu, HH; Kengatharan, MK; Lit, ES; Lu, L; Monk, J; Nguyen, QD; Shah, SM; Syed, B; Zimmer-Galler, I, 2010) |
" The safety and bioactivity of topical mecamylamine, an antagonist of nACh receptors, was tested in patients with diabetic macular edema." | 5.14 | Topical mecamylamine for diabetic macular edema. ( Campochiaro, PA; Channa, R; Cooke, JP; Do, DV; Hafiz, G; Heier, JS; Hsu, HH; Kengatharan, MK; Lit, ES; Lu, L; Monk, J; Nguyen, QD; Shah, SM; Syed, B; Zimmer-Galler, I, 2010) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (60.00) | 29.6817 |
2010's | 2 (40.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Papp, M | 1 |
Gruca, P | 1 |
Lason-Tyburkiewicz, M | 1 |
Litwa, E | 1 |
Willner, P | 1 |
Campochiaro, PA | 1 |
Shah, SM | 1 |
Hafiz, G | 1 |
Heier, JS | 1 |
Lit, ES | 1 |
Zimmer-Galler, I | 1 |
Channa, R | 1 |
Nguyen, QD | 1 |
Syed, B | 1 |
Do, DV | 1 |
Lu, L | 1 |
Monk, J | 1 |
Cooke, JP | 1 |
Kengatharan, MK | 1 |
Hsu, HH | 1 |
Hentall, ID | 1 |
Sagen, J | 1 |
Hildebrand, BE | 1 |
Svensson, TH | 1 |
Hama, A | 1 |
Menzaghi, F | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Phase 2 Study of the Safety and Bioactivity of Topical Ocular Mecamylamine for the Treatment of Diabetic Macular Edema (DME)[NCT00536692] | Phase 2 | 0 participants | Interventional | 2007-09-30 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
1 trial available for mecamylamine and Chronic Disease
Article | Year |
---|---|
Topical mecamylamine for diabetic macular edema.
Topics: Administration, Topical; Adolescent; Adult; Aqueous Humor; Chronic Disease; Diabetic Retinopathy; En | 2010 |
4 other studies available for mecamylamine and Chronic Disease
Article | Year |
---|---|
Effects of chronic mild stress on the development of drug dependence in rats.
Topics: Animals; Chronic Disease; Citalopram; Depressive Disorder; Diazepam; Disease Models, Animal; Flumaze | 2014 |
Spinal CSF from rats with painful peripheral neuropathy evokes catecholamine release from chromaffin cells in vitro.
Topics: Adrenal Medulla; Animals; Catecholamines; Cattle; Cells, Cultured; Cerebrospinal Fluid; Cerebrospina | 2000 |
Intraaccumbal mecamylamine infusion does not affect dopamine output in the nucleus accumbens of chronically nicotine-treated rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Chronic Disease; Dopamine; Extracellular | 2000 |
Antagonist of nicotinic acetylcholine receptors (nAChR) enhances formalin-induced nociception in rats: tonic role of nAChRs in the control of pain following injury.
Topics: Acute Disease; Animals; Chronic Disease; Male; Mecamylamine; Nicotinic Antagonists; Nociceptors; Pai | 2001 |